SynOx Therapeutics Ltd.

https://www.synoxtherapeutics.com

Twitter: @SynOx_Tx

SynOx is a clinical stage biopharmaceutical company. It is a spin out from Celleron Therapeutics Ltd, an oncology company focused on the clinical development of new and innovative therapies to treat cancer. SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue. SynOx is led by a team of experts that combines biotech and pharma experience with a successful track record of developing and bringing products to market. It is backed by a strong investor syndicate – HealthCap, Medicxi, Forbion and Gimv. *

	Start	2020-11-19 existent (s-off)
	Today	Celleron Therapeutics Ltd.
	Predecessor	Celleron Therapeutics Ltd.
	Industry	emactuzumab
	Industry 2	drug development
	Person	La Thangue, Nick (SynOx Therapeutics 202011 CEO)

	Region	Dublin
	Country	Ireland, Republic of
	City	n. a. Dublin
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: SynOx Therapeutics Ltd.. (11/19/20). "Press Release: SynOx Therapeutics Raises €37M in Series A Financing. HealthCap and Medicxi Co-lead, Joined by Forbion and Gimv". Dublin.

		Record changed: 2020-11-19

More documents for SynOx Therapeutics Ltd.

[1] SynOx Therapeutics Ltd.. (11/19/20). "Press Release: SynOx Therapeutics Raises €37M in Series A Financing. HealthCap and Medicxi Co-lead, Joined by Forbion and Gimv". Dublin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]